Tesamorelin

Tesamorelin
Clinical data
Trade names Egrifta
AHFS/Drugs.com Multum Consumer Information
MedlinePlus a611035
Pregnancy
category
  • US: X (Contraindicated)
Routes of
administration
Subcutaneous injection
ATC code H01AC06 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability ≤4%[1]
Metabolism Proteolysis
Biological half-life 26–38 min
Excretion Renal/proteolysis
Identifiers
CAS Number 901758-09-6 YesY
PubChem (CID) 16137828
ChemSpider 34982925
UNII MQG94M5EEO YesY
KEGG D09015 YesY
Chemical and physical data
Formula C221H366N72O67S
Molar mass 5135.86 g/mol
3D model (Jmol) Interactive image

Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.[2]

See also

References


This article is issued from Wikipedia - version of the 9/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.